Teva shares climb after FDA approves its generic EpiPen | Financial Times
Teva Retests Lows After Judge Declines Settlement Offer
Why You Should Still Buy Teva (NYSE:TEVA) | Seeking Alpha
With 61% ownership of the shares, Teva Pharmaceutical Industries Limited (NYSE:TEVA) is heavily dominated by institutional owners - Simply Wall St News
Teva Stock Price Rises - Wise Money Israel
Teva's shares surge as first quarter results beat expectations | The Times of Israel
Teva shares rally as FDA approves troubled drugmaker's migraine treatment | The Times of Israel